Clinical Trial Update: Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of TLK286 for platinum-resistant advanced epithelial ovarian cancer has completed. The update does not include results in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• TLK286

Snippet

Sponsor: Telik | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED